COX-2 promoter polymorphisms and the association with prostate cancer risk in South African men

Simple item page
dc.contributor.authorFernandez P.
dc.contributor.authorDe Beer P.M.
dc.contributor.authorVan der Merwe L.
dc.contributor.authorHeyns C.F.
dc.date.accessioned2011-05-15T16:15:52Z
dc.date.available2011-05-15T16:15:52Z
dc.date.issued2008
dc.description.abstractCyclooxygenase-2 (COX-2) converts arachidonic acid to prostaglandins, which are important mediators of cell proliferation and inflammation. Evidence indicates that COX-2 plays a role in carcinogenesis and that it is over-expressed in prostate tumours. We investigated the role of COX-2 variants in prostate cancer in a case-control study of South African Coloured men, consisting of 151 cases and 134 controls. The genotype frequencies of four single-nucleotide polymorphisms (SNPs) in the COX-2 promoter were initially determined in 50 control subjects. One SNP, rs20417 (-899G>C), was monomorphic and excluded from further investigation. Three SNPs, rs3918304 (-1285A>G), rs20415 (-1265C>T) and rs5270 (-297C>G), were genotyped in all the case patients and control subjects. The -1285 G-allele and -1265 T-allele were associated with increased risk of prostate cancer [odds ratio (OR)=3.53; confidence interval (CI) = 2.14-5.90; P < 0.0001 and OR = 3.01; CI = 1.82-5.02; P < 0.0001] after adjusting for age. Haplotype GTC conferred increased risk of prostate cancer in South African Coloured men (OR = 3.54 versus ACC; CI = 2.12-5.92; P < 0.0001). These findings in conjunction with findings in other populations of African descent might suggest a common causal variant for prostate cancer in COX-2, or a variant in a nearby gene. © The Author 2008. Published by Oxford University Press. All rights reserved.
dc.description.versionArticle
dc.identifier.citationCarcinogenesis
dc.identifier.citation29
dc.identifier.citation12
dc.identifier.issn01433334
dc.identifier.other10.1093/carcin/bgn245
dc.identifier.urihttp://hdl.handle.net/10019.1/13525
dc.subjectadenosine
dc.subjectcyclooxygenase 2
dc.subjectcytidine
dc.subjectguanosine
dc.subjectthymidine
dc.subjectadult
dc.subjectage
dc.subjectaged
dc.subjectarticle
dc.subjectcancer risk
dc.subjectcarcinogenesis
dc.subjectcase control study
dc.subjectcontrolled study
dc.subjectgene frequency
dc.subjectgenetic association
dc.subjectgenetic risk
dc.subjectgenetic variability
dc.subjectgenotype
dc.subjecthaplotype
dc.subjecthigh risk population
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectpriority journal
dc.subjectpromoter region
dc.subjectprostate cancer
dc.subjectprostatectomy
dc.subjectsingle nucleotide polymorphism
dc.subjectSouth Africa
dc.subjecttransurethral resection
dc.subjectAfrican Continental Ancestry Group
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectCase-Control Studies
dc.subjectCyclooxygenase 2
dc.subjectGenetic Predisposition to Disease
dc.subjectGenotype
dc.subjectHaplotypes
dc.subjectHumans
dc.subjectLinkage Disequilibrium
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPolymorphism, Single Nucleotide
dc.subjectPromoter Regions, Genetic
dc.subjectProstatic Neoplasms
dc.subjectRisk Factors
dc.subjectSouth Africa
dc.titleCOX-2 promoter polymorphisms and the association with prostate cancer risk in South African men
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Tygerberg Hospital Publications